Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Recommendation of “Moderate Buy” by Brokerages

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) has been assigned a consensus rating of “Moderate Buy” from the ten ratings firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, eight have given a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $19.00.

A number of brokerages have recently issued reports on LXEO. HC Wainwright cut their price objective on shares of Lexeo Therapeutics from $13.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, January 13th. Cantor Fitzgerald began coverage on Lexeo Therapeutics in a report on Monday, December 1st. They set an “overweight” rating and a $19.00 price target on the stock. Wall Street Zen upgraded shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Oppenheimer restated an “outperform” rating and issued a $20.00 price objective on shares of Lexeo Therapeutics in a report on Wednesday, December 10th. Finally, Raymond James Financial assumed coverage on Lexeo Therapeutics in a research note on Wednesday, December 17th. They issued a “strong-buy” rating and a $25.00 target price on the stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Allworth Financial LP boosted its holdings in Lexeo Therapeutics by 1,002.9% in the 4th quarter. Allworth Financial LP now owns 3,386 shares of the company’s stock worth $34,000 after buying an additional 3,079 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Lexeo Therapeutics by 69.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company’s stock worth $35,000 after acquiring an additional 1,459 shares during the last quarter. CWM LLC grew its stake in Lexeo Therapeutics by 150.3% during the 2nd quarter. CWM LLC now owns 10,351 shares of the company’s stock valued at $42,000 after acquiring an additional 6,216 shares in the last quarter. Ethic Inc. purchased a new stake in Lexeo Therapeutics during the 2nd quarter valued at about $44,000. Finally, Cerity Partners LLC purchased a new stake in Lexeo Therapeutics in the 2nd quarter valued at $50,000. 60.67% of the stock is currently owned by hedge funds and other institutional investors.

Lexeo Therapeutics Price Performance

LXEO stock opened at $6.31 on Monday. The firm has a 50-day moving average of $8.64 and a 200 day moving average of $7.61. The company has a market cap of $460.57 million, a P/E ratio of -2.34 and a beta of 1.79. Lexeo Therapeutics has a 1 year low of $1.45 and a 1 year high of $10.99.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.